BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 10848059)

  • 21. [Antibacterial chemotherapy in leprosy: principles, objectives and recommendations].
    Sansarricq H
    Acta Leprol; 1986; 4(3):355-62. PubMed ID: 3551474
    [No Abstract]   [Full Text] [Related]  

  • 22. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
    Deps P; Guerra P; Nasser S; Simon M
    Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy.
    Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA
    Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
    Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
    Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of three-year multidrug therapy in multibacillary leprosy patients.
    Li W; Ye G; Yang Z; Tao M; Luo J; Wang C; Ji F
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):37-40. PubMed ID: 2371263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
    Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
    Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
    Lockwood DN; Cunha Mda G
    Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy of WHO regimens in the management of leprosy patients with G6PD deficiency.
    Mysore V; al-Suwaid AR
    Int J Lepr Other Mycobact Dis; 1999 Jun; 67(2):159-61. PubMed ID: 10472369
    [No Abstract]   [Full Text] [Related]  

  • 29. Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population--Curupaiti State Hospital, Rio de Janeiro, Brazil.
    Andrade VL; Marques AB; da Cunha LH; Avelleira JR
    Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):435-40. PubMed ID: 3655459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug therapy (MDT) and leprosy control.
    Noordeen SK
    Indian J Lepr; 1990; 62(4):448-58. PubMed ID: 2086680
    [No Abstract]   [Full Text] [Related]  

  • 31. [Combination chemotherapy in leprosy].
    Leiker DL
    Ned Tijdschr Geneeskd; 1986 Oct; 130(43):1926-9. PubMed ID: 3774040
    [No Abstract]   [Full Text] [Related]  

  • 32. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinations involving dapsone, rifampin, clofazimine, and ethionamide in the treatment of M. leprae infections in mice.
    Shepard CC
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):135-9. PubMed ID: 945234
    [No Abstract]   [Full Text] [Related]  

  • 34. Renal hypersensitivity vasculitis associated with dapsone.
    Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Rabel-Filho OC; Martini-Filho D; Fontes CJ
    Am J Kidney Dis; 2005 Oct; 46(4):e51-3. PubMed ID: 16183407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
    Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical and hematological side effects of clofazimine in leprosy patients.
    Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
    Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antileprosy drugs, pregnancy and fetal outcome.
    Bhargava P; Kuldeep CM; Mathur NK
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):457-8. PubMed ID: 9030117
    [No Abstract]   [Full Text] [Related]  

  • 38. [Combination drug therapy in leprosy].
    Terencio de las Aguas J
    Acta Leprol; 1983; 1(3):143-50. PubMed ID: 6359802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
    Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.